| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia
2 Discipline of Surgery, The University of Sydney, Sydney, New South Wales 2006, Australia
3 Department of Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia
4 Discipline of Medicine, The University of Sydney, Sydney, New South Wales 2006, Australia
Correspondence: Address correspondence and reprint requests to: John F. Thompson, MD, Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia; E-mail: thompson{at}smu.org.au.
Background: It has been suggested that performing a sentinel node biopsy (SNB) in patients with cutaneous melanoma increases the incidence of in-transit metastasis (ITM).
Methods: ITM rates for 2018 patients with primary melanomas 
1.0 mm thick treated at a single institution between 1991 and 2000 according to 3 protocols were compared: wide local excision (WLE) only (n = 1035), WLE plus SNB (n = 754), and WLE plus elective lymph node dissection (n = 229).
Results: The incidence of ITM for the three protocols was 4.9%, 3.6%, and 5.7%, respectively (not significant), and as a first site of recurrent disease the incidence was 2.5%, 2.4%, and 4.4%, respectively (not significant). The subset of patients who were node positive after SNB and after elective lymph node dissection also had similar ITM rates (10.8% and 7.1%, respectively; P = .11). On multivariate analysis, primary tumor thickness and patient age predicted ITM as a first recurrence, but type of treatment did not. Patients who underwent WLE only and who had a subsequent therapeutic lymph node dissection (n = 149) had an ITM rate of 24.2%, compared with 10.8% in patients with a tumor-positive sentinel node treated with immediate dissection (n = 102; P = .03).
Conclusions: Performing an SNB in patients with melanoma treated by WLE does not increase the incidence of ITM.
Key Words: Melanoma • In-transit metastasis • Recurrence • Sentinel node • Regional lymph node
This article has been cited by other articles:
 |
|
 |
|
  J. L. Messina and V. K. Sondak Lymphangiogenesis Induced by Surgery: A Risk for Melanoma Metastasis--Reply Arch Dermatol, January 1, 2009; 145(1): 90 - 90. [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Ross and J. E. Gershenwald How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann. Surg. Oncol., March 1, 2008; 15(3): 670 - 673. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Gervasoni Jr., S. Sbayi, and B. Cady Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann. Surg. Oncol., September 1, 2007; 14(9): 2443 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Morton, J. F. Thompson, A. J. Cochran, N. Mozzillo, R. Elashoff, R. Essner, O. E. Nieweg, D. F. Roses, H. J. Hoekstra, C. P. Karakousis, et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med., September 28, 2006; 355(13): 1307 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kretschmer, I. Beckmann, K.-M. Thoms, C. Mitteldorf, H. P. Bertsch, and C. Neumann Factors Predicting the Risk of In-Transit Recurrence After Sentinel Lymphonodectomy in Patients With Cutaneous Malignant Melanoma Ann. Surg. Oncol., August 1, 2006; 13(8): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Uren Sentinel Lymph Node Biopsy in Melanoma J. Nucl. Med., February 1, 2006; 47(2): 191 - 195. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
